Masitinib trial insurance offers a safety net for ALS research
WHY IT MATTERS
This insurance arrangement signals that AB Science is confident enough in masitinib to move forward with Phase 3 testing in ALS patients, which is a critical step toward potentially bringing a new treatment option to people living with this progressive disease.
AB Science is preparing to test an experimental drug called masitinib for ALS (a disease that affects nerve cells that control muscles). To protect their investment in this large clinical trial, the company bought special insurance that would reimburse them if the trial doesn't go as planned or costs more than expected.
As part of preparations for a Phase 3 clinical trial to test its experimental therapy, masitinib, in people with amyotrophic lateral sclerosis (ALS), AB Science has purchased a unique insurance policy. This type of insurance — called clinical trial funding insurance, or CTFI — is a specialized financial product that would essentially reimburse AB Science for costs if the […] The post Masitinib trial insurance offers a safety net for ALS research appeared first on ALS News Today .